Cargando…
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month rec...
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916343/ https://www.ncbi.nlm.nih.gov/pubmed/31638282 http://dx.doi.org/10.1111/1346-8138.15103 |
| _version_ | 1783480218764181504 |
|---|---|
| author | Yokota, Kenji Uchi, Hiroshi Uhara, Hisashi Yoshikawa, Shusuke Takenouchi, Tatsuya Inozume, Takashi Ozawa, Kentaro Ihn, Hironobu Fujisawa, Yasuhiro Qureshi, Anila de Pril, Veerle Otsuka, Yasushi Weber, Jeffrey Yamazaki, Naoya |
| author_facet | Yokota, Kenji Uchi, Hiroshi Uhara, Hisashi Yoshikawa, Shusuke Takenouchi, Tatsuya Inozume, Takashi Ozawa, Kentaro Ihn, Hironobu Fujisawa, Yasuhiro Qureshi, Anila de Pril, Veerle Otsuka, Yasushi Weber, Jeffrey Yamazaki, Naoya |
| author_sort | Yokota, Kenji |
| collection | PubMed |
| description | The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month recurrence‐free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19–2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence. |
| format | Online Article Text |
| id | pubmed-6916343 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69163432019-12-17 Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study Yokota, Kenji Uchi, Hiroshi Uhara, Hisashi Yoshikawa, Shusuke Takenouchi, Tatsuya Inozume, Takashi Ozawa, Kentaro Ihn, Hironobu Fujisawa, Yasuhiro Qureshi, Anila de Pril, Veerle Otsuka, Yasushi Weber, Jeffrey Yamazaki, Naoya J Dermatol Concise Communications The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month recurrence‐free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19–2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence. John Wiley and Sons Inc. 2019-10-22 2019-12 /pmc/articles/PMC6916343/ /pubmed/31638282 http://dx.doi.org/10.1111/1346-8138.15103 Text en © 2019 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Concise Communications Yokota, Kenji Uchi, Hiroshi Uhara, Hisashi Yoshikawa, Shusuke Takenouchi, Tatsuya Inozume, Takashi Ozawa, Kentaro Ihn, Hironobu Fujisawa, Yasuhiro Qureshi, Anila de Pril, Veerle Otsuka, Yasushi Weber, Jeffrey Yamazaki, Naoya Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study |
| title | Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study |
| title_full | Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study |
| title_fullStr | Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study |
| title_full_unstemmed | Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study |
| title_short | Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study |
| title_sort | adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage iii/iv melanoma: japanese subgroup analysis from the phase 3 checkmate 238 study |
| topic | Concise Communications |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916343/ https://www.ncbi.nlm.nih.gov/pubmed/31638282 http://dx.doi.org/10.1111/1346-8138.15103 |
| work_keys_str_mv | AT yokotakenji adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT uchihiroshi adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT uharahisashi adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT yoshikawashusuke adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT takenouchitatsuya adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT inozumetakashi adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT ozawakentaro adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT ihnhironobu adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT fujisawayasuhiro adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT qureshianila adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT deprilveerle adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT otsukayasushi adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT weberjeffrey adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study AT yamazakinaoya adjuvanttherapywithnivolumabversusipilimumabaftercompleteresectionofstageiiiivmelanomajapanesesubgroupanalysisfromthephase3checkmate238study |